Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

Compare

752 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACRS Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Aclaris

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACRS Stock 12 Month Forecast

Average Price Target

$9.40

▲(502.56%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $9.40 with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 502.56% change from the last price of $1.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.56,3.68,4.800000000000001,5.92,7.040000000000001,8.16,9.280000000000001,10.4,11.520000000000001,12.64,13.76,14.88,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.0523076923076924,2.6646153846153844,3.276923076923077,3.8892307692307693,4.501538461538462,5.113846153846154,5.726153846153846,6.338461538461539,6.950769230769231,7.563076923076924,8.175384615384615,8.787692307692307,{"y":9.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.8676923076923075,2.2953846153846156,2.723076923076923,3.1507692307692308,3.5784615384615384,4.006153846153847,4.433846153846154,4.861538461538462,5.28923076923077,5.716923076923077,6.144615384615385,6.572307692307692,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$9.40

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$16

Buy

925.64%

Upside

Reiterated

06/25/25

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Unknown AnalystWedbush

Not Ranked

Wedbush

Buy

412.82%

Upside

Reiterated

06/24/25

Aclaris Therapeutics (ACRS) Gets a Buy from Wedbush

Thomas SmithLeerink Partners

Leerink Partners

Buy

348.72%

Upside

Reiterated

05/28/25

Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments

Louise ChenScotiabank

Scotiabank

$15→$9

Buy

476.92%

Upside

Reiterated

05/09/25

Aclaris Therapeutics price target lowered to $9 from $15 at ScotiabankAclaris Therapeutics price target lowered to $9 from $15 at Scotiabank

Roger SongJefferies

Jefferies

Buy

348.72%

Upside

Reiterated

04/24/25

Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Initiated

03/18/25

Aclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldAclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$5→$2

Hold

28.21%

Upside

Reiterated

03/03/25

Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)

Christopher RaymondPiper Sandler

Piper Sandler

$13

Buy

733.33%

Upside

Reiterated

02/18/25

Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)

Julian HarrisonBTIG

BTIG

Buy

412.82%

Upside

Upgraded

11/18/24

Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$16

Buy

925.64%

Upside

Reiterated

06/25/25

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Unknown AnalystWedbush

Not Ranked

Wedbush

Buy

412.82%

Upside

Reiterated

06/24/25

Aclaris Therapeutics (ACRS) Gets a Buy from Wedbush

Thomas SmithLeerink Partners

Leerink Partners

Buy

348.72%

Upside

Reiterated

05/28/25

Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments

Louise ChenScotiabank

Scotiabank

$15→$9

Buy

476.92%

Upside

Reiterated

05/09/25

Aclaris Therapeutics price target lowered to $9 from $15 at ScotiabankAclaris Therapeutics price target lowered to $9 from $15 at Scotiabank

Roger SongJefferies

Jefferies

Buy

348.72%

Upside

Reiterated

04/24/25

Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Initiated

03/18/25

Aclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldAclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$5→$2

Hold

28.21%

Upside

Reiterated

03/03/25

Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)

Christopher RaymondPiper Sandler

Piper Sandler

$13

Buy

733.33%

Upside

Reiterated

02/18/25

Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)

Julian HarrisonBTIG

BTIG

Buy

412.82%

Upside

Upgraded

11/18/24

Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aclaris Therapeutics

1 Month

xxx

Success Rate

7/13 ratings generated profit

Average Return

-3.06%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of -3.06% per trade.

3 Months

xxx

Success Rate

5/13 ratings generated profit

Average Return

-5.88%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of -5.88% per trade.

1 Year

Roger SongJefferies

Success Rate

3/12 ratings generated profit

Average Return

-32.07%

reiterated a buy rating 2 months ago

Copying Roger Song's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -32.07% per trade.

2 Years

xxx

Success Rate

6/13 ratings generated profit

Average Return

+121.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of +121.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACRS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACRS has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACRS average Analyst price target in the past 3 months is 9.40.

Each month's total comprises the sum of three months' worth of ratings.

ACRS Financial Forecast

ACRS Earnings Forecast

Next quarter’s earnings estimate for ACRS is -$0.14 with a range of -$0.16 to -$0.12. The previous quarter’s EPS was -$0.12. ACRS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.

ACRS Sales Forecast

Next quarter’s sales forecast for ACRS is $1.32M with a range of $300.00K to $2.70M. The previous quarter’s sales results were $1.46M. ACRS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year ACRS has Outperformed its overall industry.

ACRS Stock Forecast FAQ

What is ACRS’s average 12-month price target, according to analysts?

Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is 9.40.

What is ACRS’s upside potential, based on the analysts’ average price target?

Aclaris Therapeutics has 502.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACRS a Buy, Sell or Hold?

Aclaris Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Aclaris Therapeutics’s price target?

The average price target for Aclaris Therapeutics is 9.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $7.00. The average price target represents 502.56% Increase from the current price of $1.56.

What do analysts say about Aclaris Therapeutics?

Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ACRS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

ACRS Analyst Ratings

ACRS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aclaris Therapeutics

ACRS Analyst Recommendation Trends

ACRS Financial Forecast

ACRS Earnings Forecast

ACRS Sales Forecast

ACRS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts